Effect of neoadjuvant therapy on general anesthesia and recovery

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091433

Enrollment

Unknown

Registered

2024-10-28

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of neoadjuvant therapy on anesthesia and recovery quality in patients with esophageal cancer

Interventions

experimental group (neoadjuvant therapy):None

control group (did not participate in neoadjuvant therapy):None

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Elective radical resection of esophageal cancer under general anesthesia in patients with grade ASA(American Standars Association)I~II.

Exclusion criteria

Exclusion criteria: Preoperative complicated with severe heart, lung, liver and kidney diseases; Allergy to the investigational drug; Any diseases of the central nervous system; Hearing impairment; History of long-term use of sedatives, analgesics, alcohol dependence; Patient rejection.

Design outcomes

Primary

Measure	Time frame
Ventricular target concentration of propofol effects during sleep(ug/ml);Bispectral index of EEG during sleep;Total intraoperative dosage of propofol;Total intraoperative dosage of remifentanil;	—

Secondary

Measure	Time frame
Patient's vital signs while asleep;Patient's vital signs during recovery;Adverse reactions during recovery;	—

Countries

China

Contacts

Public ContactXU Xiaoling; XU Xiang

Cancer Hospital of Shantou University Medical College

xuxiang716@sina.cn+86 134 2533 0422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026